Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals (JAZZ) insider Patricia Carr, SVP and Chief Accounting Officer, reported option-related share transactions. On November 18, 2025, she exercised a non-qualified stock option covering 5,250 ordinary shares at an exercise price of $136.18 per share, increasing her direct shareholdings. On the same date, she reported two sales of ordinary shares: one for 69 shares at $181.66 per share and another for 5,250 shares at $182.07 per share. After these transactions, she directly owned 7,012 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc (JAZZ) director Rick E. Winningham reported a sale of company stock. On 11/18/2025, he sold 5,500 ordinary shares of Jazz Pharmaceuticals at a price of $180.8597 per share. After this transaction, he beneficially owned 8,893 ordinary shares, held directly. This filing is a routine disclosure of insider trading activity required under securities regulations.
Jazz Pharmaceuticals plc executive Robert Iannone, EVP, Global Head of R&D & CMO, reported a stock sale in a Form 4 filing. On 11/17/2025, he sold 7,159 ordinary shares of JAZZ at $168.26 per share in a transaction carried out under a pre-arranged Rule 10b5-1 trading plan. After this sale, he beneficially owned 72,628 ordinary shares. A footnote notes that he had previously acquired 166 ordinary shares on May 30, 2025 under a Section 423 Employee Stock Purchase Plan.
Jazz Pharmaceuticals plc reported positive top-line results from its Phase 3 HERIZON-GEA-01 trial. The study evaluated Ziihera® (zanidatamab-hrii) with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. These initial results suggest that Ziihera-based combinations may offer a new treatment option in this hard-to-treat cancer setting, pending full data and any future regulatory decisions. Details of the results are provided in a press release attached as an exhibit.
Jazz Pharmaceuticals plc reported higher Q3 results while reshaping its portfolio and balance sheet. Total revenue was $1,126,107, up from $1,054,969 a year ago, driven by product sales. Quarterly net income reached $251,412 versus $215,055 last year as a large income tax benefit offset higher operating costs.
Year to date, the company booked a net loss, reflecting significant acquired in‑process R&D tied to the April acquisition of Chimerix for cash consideration of $944.2 million. Operating cash flow remained strong at $993,255 for the nine months. Cash and cash equivalents were $1,326,070 with investments of $720,000. Total debt stood at $5,361,161, following a voluntary $750.0 million term‑loan repayment in January; the 2026 notes now sit in current maturities.
Pipeline and portfolio updates include FDA approval in October 2025 expanding Zepzelca’s maintenance use in extensive‑stage SCLC, FDA accelerated approval of Modeyso in August 2025, and prior U.S./EU authorizations for Ziihera. In August 2025, Jazz licensed SAN2355 from Saniona with a $42.5 million upfront, expensed to IPR&D.
Jazz Pharmaceuticals plc furnished a Current Report on Form 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and will not be incorporated by reference into other SEC filings. The report was signed by Executive Vice President and CFO Philip L. Johnson on November 5, 2025.
Jazz Pharmaceuticals appointed Dr. Ted Love to its Board of Directors, effective December 1, 2025, as a Class I director with a term expiring at the 2027 annual general meeting. He will serve on the Audit Committee and the Science and Medicine Committee. Compensation will follow the company’s standard non-employee director program, and he will enter into the company’s standard indemnification agreement.
Kenneth W. O’Keefe will retire from the Board effective December 1, 2025. The company stated his decision was not due to any dispute or disagreement regarding its operations, policies, or practices.
Jazz Pharmaceuticals (JAZZ) entered a comprehensive settlement with Avadel resolving all ongoing U.S. litigation between the companies. Jazz will grant Avadel an immediate license to any Jazz patents covering Lumryz for FDA-approved narcolepsy uses, and a second license effective March 1, 2028 for any other future indications.
Financial terms are twofold. Avadel will pay Jazz royalties of 3.85% (subject to a potential reduction to 3.75%) on net sales of Lumryz for narcolepsy uses beginning October 1, 2025. For non‑narcolepsy uses starting March 1, 2028, royalties are 10% (subject to a potential reduction to 9.5%). If Avadel makes unpermitted non‑narcolepsy sales before March 1, 2028, it will owe 80% of such net sales to Jazz from October 1, 2025 through February 29, 2028.
Cash impact and accounting. Jazz will pay a lump‑sum $90 million to settle Avadel’s pending claims and will waive court‑ordered royalties on Lumryz sales through September 30, 2025. Jazz expects to record an approximately $90 million pre‑tax charge in Q3 2025 and plans to use cash on hand. Avadel grants a covenant not to sue Jazz’s Xywav or Xyrem, and Jazz did not agree to waive Orphan Drug Exclusivity for Xywav in idiopathic hypersomnia. The parties will file to dismiss the proceedings.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales under a Rule 10b5-1 trading plan. On 10/01/2025 he sold 2,000 ordinary shares at $131.78, reducing his beneficial holdings to 412,326 shares. On 10/03/2025 he sold an additional 3,500 shares at $140.00, reducing holdings to 408,826 shares. The Form 4 is signed by an attorney-in-fact and notes the transactions were executed pursuant to the disclosed 10b5-1 plan.
Jazz Pharmaceuticals plc insider filing reports a proposed sale of 3,500 common shares to be executed on or about 10/03/2025 through Merrill Lynch on Nasdaq, with an aggregate market value of $490,000. The filing shows those shares were originally acquired as executive compensation on 10/04/2021 and 11/01/2021 (totaling 3,500 shares). The filer, identified as Bruce C Cozadd in prior sales records, disclosed three prior sales in the past three months totaling 9,000 shares for combined gross proceeds of $1,148,460 (sales on 08/01/2025, 09/02/2025, and 10/01/2025). The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.